期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

分子靶向药物索拉菲尼对胃癌细胞株SNU-1增殖的影响

下载PDF
导出
摘要 目的研究分子靶向药物索拉菲尼对胃癌SNU-1细胞株的抑制作用。方法分别以不同浓度索拉菲尼作用于胃癌SNU-1细胞株,采用MTT法分别检测不用浓度药物组对胃癌细胞SNU-1的抑制作用。结果在相同的药物浓度下,随着作用时间(24 h、48 h、72 h)的延长,索拉菲尼对人胃癌SNU-1细胞的生长抑制作用逐渐增强(P<0.05),在相同的干预时间,随着药物浓度的增加,索拉菲尼对人胃癌SNU-1细胞的生长抑制作用也逐渐增强(P<0.05)。结论索拉菲尼可抑制体外胃癌SNU-1细胞株的增殖,为在临床治疗胃癌提供基础依据。
作者 陈晓萌 樊鹏利 秦玉花 赵红卫
机构地区 河南省人民医院
出处 《中国医药指南》 2015年第15期57-58,共2页 Guide of China Medicine
关键词 靶向药物 索拉菲尼 胃癌 抑制作用
分类号 R735.2 [医药卫生—肿瘤]
  • 相关文献

参考文献8

  • 1Mina S,Bohn BA,Simon R,et al.PTEN deletion is rare but often homogeneous in gastric cancer[J].Clinical Pathology,2012,65(8):693-698.
  • 2Zhu XH,Qin X,Fei MG,et al.Loss and reduced expression of PTEN correlate with advanced stage gastric carcinoma[J].Experimen Therapeu Med,2013,5(1):57-64.
  • 3Roukos DH.Targeting gastric cancer with trastuzumab:new clinical practice and innovative developments to overcome resistance[J].Ann Surg Oncol,2010,17(1):14-17.
  • 4Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibits broad Spectrum oral antitumor activity and targets the RAS/RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res,2004,64(19):7099-7109.
  • 5Strumberg D.Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment[J].Drugs Today(Barc),2005,41(12):773-784.
  • 6Wilhelm SM,Carter C,Tang L,et al.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAS/RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis[J].Cancer Res,2004,64(19):7099-7109.
  • 7Liu L,Cao Y,Chen C,et al.Sorfenib blocks the RAF/MEK/ERK pathway,inhibits tumor angiogenesis and induce tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5[J].Cancer Res,2006,66(24):l1851-11858.
  • 8孙广涛,邱伟华,施敏敏,陈皓.索拉菲尼对肝癌细胞HepG2自噬的抑制作用[J].外科理论与实践,2010,15(1):51-55. 被引量：9

二级参考文献10

  • 1White E, DiPaola RS. The double-edged sword of autophagy modulation in cancer[J]. Clin Cancer Res,2009, 15(17):5308-5316.
  • 2Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocel|ular carcinoma [J]. N Engl J Med, 2008,359(4):378-390.
  • 3He C, Klionsky DJ. Regulation mechanisms and signaling pathways of autophagy[J]. Annu Rev Genet,2009,43:67- 93.
  • 4Liu L, Cao Y, Chert C, et al. Sorafenib blocks the RAF/ MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 [J]. Cancer Res,2006,66 (24):11851- 11858.
  • 5Sivaprasad U, Basu A. Inhibition of ERK attenuates autophagy and potentiates turnout necrosis factor induced cell death in MCF-7 cells [J]. J Cell Mol Med, 2008,12(4): 1265-1271.
  • 6Chang CP, Yang MC, Liu HS, et al. Concanavalin A induces autophagy in hepatoma cells and has a therapeutic effect in a routine in situ hepatoma model[J]. Hepatology,2007,45(2):286-296.
  • 7Gao M, Yeh PY, Lu YS, et al. OSU-03012, a novel celecoxib derivative, induces reactive oxygen species- related autophagy in hepatocellular carcinoma[J]. Cancer Res,2008,68(22):9348-9357.
  • 8Brech A, Ahlquist T, Lothe RA, et al. Autophagy in turnout suppression and promotion[J]. Mol Oncol 2009,3 (4):366-375.
  • 9Longo L, Platini F, Scardino A, el al. Autophagy inhibition enhances anthocyanin-inducecl apoptosis in hepatocellular carcinoma[J]. Mol Cancer Ther,2008,7(8): 2476-2485.
  • 10Luo S, Rubinsztein DC. Atg5 and Bcl-2 provide novel insights into the interplay between apoptosis and autophagy[J]. Cell Death Differ,2007,14(7):1247-1250.

共引文献8

中国医药指南
2015年 第15期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部